Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44259 | 0.79 | IDO1 (0.44) | IDO1NOS3NOS1NOS2MAOB | |
| SCHEMBL2074627 | 0.79 | IDO1 (0.44) | IDO1NOS3NOS1NOS2MAOB | |
| SCHEMBL10986671 | 0.78 | CYP1A2 (0.50) | NOS1MAOBHSD17B10MAOACYP1A2 | |
| Benzyl Thiocyanate SCHEMBL27730692 | 0.75 | MAOB (0.48) | IDO1NOS3NOS1NOS2MAOB | |
| SCHEMBL9217746 | 0.75 | MAOB (0.44) | IDO1NOS3NOS1NOS2MAOB | |
| Benzyl Thiocyanate SCHEMBL129196 | 0.75 | MAOB (0.48) | IDO1NOS3NOS1NOS2MAOB | |
| SCHEMBL28515 | 0.75 | CTSL (0.43) | IDO1NOS3NOS1NOS2MAOB | |
| SCHEMBL10978005 | 0.75 | CYP1A2 (0.42) | IDO1NOS3NOS1NOS2MAOB | |
| SCHEMBL11384559 | 0.75 | CYP1A2 (0.42) | IDO1NOS3NOS1NOS2MAOB | |
| SCHEMBL19514760 | 0.75 | CA12 (0.43) | IDO1NOS3NOS1NOS2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| CN-101707247-B | Anode and battery | SONY CORP | 2013-03-27 | — | — | CN | claimed |
| EP-2482856-A2 | MICELLAR COMPOSITIONS FOR USE IN BIOLOGICAL APPLICATIONS | KINGS COLLEGE LONDON (GB) | 2012-08-08 | — | — | EP | claimed |
| WO-2011039535-A2 | MICELLAR COMPOSITIONS FOR USE IN BIOLOGICAL APPLICATIONS | KING'S COLLEGE LONDON (GB) | 2011-04-07 | — | — | WO | claimed |
| EP-1178958-B1 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2004-02-18 | — | — | EP | claimed |
| EP-0865339-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2003-01-22 | — | — | EP | claimed |
| EP-0735062-B1 | ACTINIC-RADIATION-CURABLE COMPOSITION AND LENS SHEET | MITSUBISHI RAYON CO (JP) | 2002-01-30 | — | — | EP | claimed |
| EP-0093010-B1 | ALPHA-HYDROXYETHYLPHOSPHINATES, AND THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-06-11 | — | — | EP | claimed |
| EP-0076557-B1 | PEPTIDES AND PSEUDOPEPTIDES IN WHICH THE N TERMINUS BEARS TWO SUBSTITUENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-11-13 | — | — | EP | claimed |
| US-12065448-B2 | Heteroaryl plasma kallikrein inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-20 | — | — | US | disclosed |
| WO-2024059186-A1 | N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| US-20220298176-A1 | HETEROARYL PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-22 | — | — | US | disclosed |
| CN-115044923-A | Method for preparing 2-aryl-3-thiocyano-benzothiophene by using electrochemical reaction | 盐城师范学院 | 2022-09-13 | — | — | CN | disclosed |
| EP-4031245-A1 | HETEROARYL PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2022-07-27 | — | — | EP | disclosed |
| WO-2011039535-A2 | MICELLAR COMPOSITIONS FOR USE IN BIOLOGICAL APPLICATIONS | KING'S COLLEGE LONDON (GB) | 2011-04-07 | — | — | WO | disclosed |
| CN-101707247-A | Anode and battery | SONY CORP | 2010-05-12 | — | — | CN | disclosed |
| CN-1964102-A | Anode and battery | SONY CORP (JP) | 2007-05-16 | — | — | CN | disclosed |
| CN-1806356-A | Method of producing membrane electrode assemblies | CABOT CORP (US) | 2006-07-19 | — | — | CN | disclosed |
| US-20060099512-A1 | Anode and battery | MURATA MANUFACTURING CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-5478959-A | Method for preparing 1,2-dithiins and precursors of 1,2-dithiins | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1995-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298176-A1 | HETEROARYL PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | IDO1 1643/4885NOS3 1858/4885NOS1 3034/4885 |
| US-12065448-B2 | Heteroaryl plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | IDO1 1643/4885NOS3 1858/4885NOS1 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.